Child cured of HIV: can this be repeated?

Abstract:

:Eradication of HIV infection is the most challenging research area in the HIV/AIDS field. Treatment of HIV infection with antiretrovirals halts viral replication but fails to eradicate infection because it does not eliminate latent viruses. Eradication has only been achieved in one exceptional case after bone marrow transplantation. For this reason, researchers were surprised by a report describing the first cure of an HIV-infected individual using antiretrovirals. It was an in utero HIV-infected newborn treated immediately after birth with a potent antiretroviral combination. After treatment interruption, the child showed no evidence for active HIV infection; she was apparently cured. The case is particular and can be seen as an extreme case of postexposure prophylaxis. Moreover, due to strong immunological differences between newborns and adults, the case does not provide new hope for adult HIV-infected individuals, although it may open new treatment standards for functional cure of HIV-infected newborns. However, new studies to proof the benefit of immediate treatment of HIV-exposed newborns will require the definition of point of care diagnostic tools, drug regimens and the minimal time from birth to therapy introduction, and also importantly, when and under what settings should treatment be interrupted to test for functional cure.

authors

Blanco J

doi

10.1517/14656566.2013.835396

subject

Has Abstract

pub_date

2013-12-01 00:00:00

pages

2307-9

issue

17

eissn

1465-6566

issn

1744-7666

journal_volume

14

pub_type

社论
  • Treating diabetic ulcers.

    abstract:INTRODUCTION:Diabetic foot ulceration is a serious secondary complication of diabetes mellitus and the most common cause of hospitalization in diabetic patients. The etiology of diabetic foot ulcerations is complex due to their multifactorial nature. Thus, addressing all of the factors involved remains instrumental in ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.530658

    authors: Tecilazich F,Dinh T,Veves A

    更新日期:2011-03-01 00:00:00

  • Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.

    abstract:BACKGROUND:Patients with rheumatoid arthritis (RA) have an increased risk of atherosclerotic cardiovascular disease which cannot be explained by traditional cardiovascular risk factors alone. Atherosclerosis is considered an inflammatory condition and inflammation experienced in RA may contribute to accelerated atheros...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.7.1121

    authors: Avouac J,Allanore Y

    更新日期:2008-05-01 00:00:00

  • Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin.

    abstract::Despite the revolutionary introduction of antibiotic therapy in the post-World War II era, primary care physicians continue to struggle with the issue of optimal treatment strategies for bacterial infection and the growing problem of antimicrobial resistance. The aggressive use of potent agents as first-line therapy m...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.2.229

    authors: Nicolau DP

    更新日期:2004-02-01 00:00:00

  • Advances in pharmacotherapy of vestibular and ocular motor disorders.

    abstract:INTRODUCTION:Vertigo and dizziness are common chief complaints of vestibular and ocular motor disorders (lifetime prevalence 30%). Treatment relies on physical, pharmacological, psychological and rarely surgical approaches. Eight groups of drugs are currently used in vestibular and ocular motor disorders, namely anti-v...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1610386

    authors: Zwergal A,Strupp M,Brandt T

    更新日期:2019-07-01 00:00:00

  • Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.

    abstract:IMPORTANCE OF THE FIELD:The emergence of fixed-combination drugs for the treatment of glaucoma has, to some extent, changed the medical management of glaucoma. The potential benefits of these drugs include a reduction in the total number of drops and preservatives instilled per day and improved patient comfort factors,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656561003667540

    authors: Razeghinejad MR,Sawchyn AK,Katz LJ

    更新日期:2010-04-01 00:00:00

  • Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.

    abstract:INTRODUCTION:In the 40-50% of advanced melanoma patients with tumors harboring BRAF V600E and V600 K mutations, BRAF inhibitors such as dabrafenib are a highly effective treatment. However, most patients develop resistance after several months on treatment. The addition of a MEK inhibitor, such as trametinib, to BRAF i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1168805

    authors: Spain L,Julve M,Larkin J

    更新日期:2016-01-01 00:00:00

  • BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.

    abstract:INTRODUCTION:BRAF inhibition alone has achieved unprecedented efficacy results in patients affected by BRAF-mutated advanced melanoma. Since these findings, it was postulated that dual inhibition of BRAF and other components of the RAS/RAF/MEK/ERK MAPK pathway (such as MEK) would be superior to BRAF inhibition as monot...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1044971

    authors: Richman J,Martin-Liberal J,Diem S,Larkin J

    更新日期:2015-06-01 00:00:00

  • Daily versus intermittent corticosteroids for the treatment of mild persistent asthma.

    abstract::Asthma is a chronic disease of the airways in which inflammation causes bronchial hyper-reactivity and attacks of wheezing, dyspnea and chest tightness that are triggered by various agents. It requires both acute treatment of the paroxistical respiratory symptoms with reliever medications and maintenance treatment, wh...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.7.9.1235

    authors: Antoniu SA

    更新日期:2006-06-01 00:00:00

  • Pharmacotherapy of hypercholesterolaemia: statins in clinical practice.

    abstract::The objective of this article is to evaluate the roles of the lipid-lowering class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in reducing cardiovascular events and to review their mechanism of action based on in vitro and in vivo studies. The clinical outcome of 15 major clinical...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.4.683

    authors: Moghadasian MH,Mancini GB,Frohlich JJ

    更新日期:2000-05-01 00:00:00

  • The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin.

    abstract::Gestational diabetes (GD) develops because pregnancy increases requirements for insulin secretion while increasing insulin resistance. Women with GD often have impaired pancreatic beta-cell compensation for insulin resistance. The nature of GD is currently contentious, with debate about its existence, diagnosis and ra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.11.1557

    authors: Glueck CJ,Goldenberg N,Streicher P,Wang P

    更新日期:2002-11-01 00:00:00

  • The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.

    abstract::A randomized Phase III trial tested the efficacy of pemetrexed as maintenance treatment in patients with advanced non-small-cell lung cancer (NSCLC) who were without progression after completing four cycles of first-line platinum-based chemotherapy. The primary endpoint of the trial was progression-free survival (PFS)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14656560903485672

    authors: Gridelli C,Di Maio M

    更新日期:2010-02-01 00:00:00

  • Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.

    abstract::Venous thromboembolism is a frequent, life-threatening, postoperative complication of hip-fracture and total-knee-replacement surgery. Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation. Low molecular weight heparins, such as enoxapa...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,杂志文章,评审

    doi:10.1517/14656566.3.4.455

    authors: Doggrell SA

    更新日期:2002-04-01 00:00:00

  • Chemotherapeutic inhibitors in the treatment of prostate cancer.

    abstract:INTRODUCTION:Prostate cancer being the second leading cause of death in men in Western countries remains a major challenge in healthcare. Several novel agents targeting signaling pathways in prostate cancer have recently been approved by the US Food and Drug Administration (FDA) but there is still an unmet need for new...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.852184

    authors: Deshmukh RR,Schmitt SM,Hwang C,Dou QP

    更新日期:2014-01-01 00:00:00

  • Stiripentol and vigabatrin current roles in the treatment of epilepsy.

    abstract:INTRODUCTION:Stiripentol and vigabatrin are the two anticonvulsant drugs currently approved in severe infantile-onset epilepsies, respectively Dravet syndrome and infantile spasms. AREAS COVERED:For both, the indication was discovered by chance thanks to an exploratory study. Both demonstrated indisputable efficacy th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1161026

    authors: Chiron C

    更新日期:2016-06-01 00:00:00

  • Vinflunine for the treatment of breast cancer.

    abstract:INTRODUCTION:Breast cancer is the most frequently diagnosed cancer and the highest cause of cancer mortality in females worldwide. The development of drugs improving overall survival in late-stage metastatic breast cancer remains a challenge. Vinflunine is the most recently developed drug in the vinca alkaloid class. I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1217991

    authors: Gourmelon C,Bourien H,Augereau P,Patsouris A,Frenel JS,Campone M

    更新日期:2016-09-01 00:00:00

  • Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future.

    abstract::Maximal surgical debulking and radiotherapy have been the cornerstone of therapy for high-grade gliomas. The impact of chemotherapy on outcome has been marginal and, until recently, its usage has been debatable. The development of new drugs and an improved understanding of chemoresistance have reinvigorated interest i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.6.749

    authors: Cavaliere R,Newton H

    更新日期:2006-04-01 00:00:00

  • Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy.

    abstract::Amyotrophic [corrected] lateral sclerosis (ALS) is a progressive degenerative condition of motor neurons that is ultimately fatal. Even though scientific discovery over the past few decades has led to a greater understanding of the pathogenic mechanisms of ALS, effective pharmacotherapy intended to slow, arrest or rev...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.4.735

    authors: Weiss MD,Weydt P,Carter GT

    更新日期:2004-04-01 00:00:00

  • State-of-the-art pharmacotherapy for diabetic neuropathy.

    abstract:INTRODUCTION:The global epidemic of diabetes has led to an epidemic of diabetes complications. Diabetic neuropathy is the most common microvascular complication, of which diabetic peripheral neuropathy (DPN) and autonomic neuropathy (AN) are the most prevalent, affecting ~50% of patients. DPN results in pain with a poo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1812578

    authors: Azmi S,Alam U,Burgess J,Malik RA

    更新日期:2021-01-01 00:00:00

  • Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder.

    abstract::The International Continence Society has defined overactive bladder (OAB) as urinary urgency, with or without urge urinary incontinence, usually with urinary frequency and nocturia. Approximately 17% of men and women in the US report OAB symptoms, which can affect quality of life. Trospium chloride, which has recently...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.8.1409

    authors: Zinner NR

    更新日期:2005-07-01 00:00:00

  • Treatment advances in non-Hodgkin's lymphoma.

    abstract::Non-Hodgkin's lymphomas (NHL) encompass a heterogeneous group of lymphoid malignancies with varying natural histories and prognoses. Recent classifications for NHL have defined distinct lymphoma entities based on morphology, immunophenotype, genetic features, clonal cell lineage and clinical features. These new, more ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.3.451

    authors: Tan BR,Bartlett NL

    更新日期:2000-03-01 00:00:00

  • Is vaccine therapy the future in cancer prevention?

    abstract::One vaccine designed to prevent cancer by preventing a precursor infection is already in common use, and at least one more is in the latter stages of clinical development. These vaccines are part of a new era of cancer immunoprophylaxis. Several further vaccines are in preclinical and clinical development, targeted at...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.5.12.2427

    authors: Frazer I

    更新日期:2004-12-01 00:00:00

  • TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.

    abstract::There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commissio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.1.75

    authors: Mikuls TR,Moreland LW

    更新日期:2001-01-01 00:00:00

  • Chemoradiotherapy for lung cancer.

    abstract::Chemoradiotherapy is a standard treatment for both unresectable locally advanced non-small cell lung cancer and limited-stage small cell lung cancer. Cisplatin-based chemotherapy with concurrent thoracic radiotherapy yields a 5-year survival rate of approximately 15% for patients with unresectable locally advanced non...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.16.2793

    authors: Ohe Y

    更新日期:2005-12-01 00:00:00

  • Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments.

    abstract::Introduction: Body dysmorphic disorder is a debilitating disorder that often presents with significant delusionality, low insight, and both medical and psychiatric comorbidities, presenting a challenge for treatment and long-term management. Its typically chronic course requires that therapy be continued indefinitely,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1610385

    authors: Dong N,Nezgovorova V,Hong K,Hollander E

    更新日期:2019-07-01 00:00:00

  • Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

    abstract:INTRODUCTION:Glioblastoma multiforme (GBM) is the most common high grade primary brain tumor in adults. Despite significant advances in treatment, the prognosis remains poor. Bevacizumab (BVZ) and irinotecan (CPT-11) are currently being investigated in the treatment of GBM patients. Although treatment with BVZ and irin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.566558

    authors: Jakobsen JN,Hasselbalch B,Stockhausen MT,Lassen U,Poulsen HS

    更新日期:2011-04-01 00:00:00

  • Pharmacotherapy of large B-cell lymphoma.

    abstract:BACKGROUND:Constituting approximately 30% of lymphoid malignancies, diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma in adults worldwide. The clinical and biologic heterogeneity that exists in DLBCL suggests that this entity might actually be comprised of several distinct neoplasms that coul...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.13.2247

    authors: Escalón MP,Lossos IS

    更新日期:2008-09-01 00:00:00

  • Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.

    abstract:INTRODUCTION:Docetaxel and paclitaxel are among the most active agents for the treatment of breast cancer. These first-generation taxanes are extremely hydrophobic; therefore, solvents are needed for its parenteral administration. Albumin nanoparticle technology allows for the transportation of such hydrophobic drugs w...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.651127

    authors: Guarneri V,Dieci MV,Conte P

    更新日期:2012-02-01 00:00:00

  • Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy.

    abstract::Introduction: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases and represents a leading cause of sudden cardiac death as well as a prevalent cause of heart failure and stroke. HCM is characterized by a very complex pathophysiology, consisting of heterogeneous clinical manifestations a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1702023

    authors: Spoladore R,Fragasso G,Pannone L,Slavich M,Margonato A

    更新日期:2020-02-01 00:00:00

  • Second line treatment options for pancreatic cancer.

    abstract:INTRODUCTION:Patients with advanced pancreatic cancer (APC) refractory to first-line therapy have a dismal prognosis and limited therapeutic options, with only one option consisting of nanoliposomal irinotecan in combination with fluorouracil and folinic acid which was approved by FDA based upon results of the phase II...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369955

    authors: Passero FC Jr,Saif MW

    更新日期:2017-10-01 00:00:00

  • The therapeutic management of differentiated thyroid cancer.

    abstract:BACKGROUND:The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor. Although it may be diffi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.15.2627

    authors: Sipos JA,Mazzaferri EL

    更新日期:2008-10-01 00:00:00